Curi RMB Capital LLC Sells 85,212 Shares of Kenvue Inc. $KVUE

Key Points

• Curi RMB Capital LLC reduced its stake in Kenvue Inc. by 15.2%, selling 85,212 shares and holding 474,957 shares valued at approximately $11.39 million as of recent filings.
• Several analysts have lowered their price targets for Kenvue, with Bank of America adjusting it from $27.00 to $25.00, while Zacks Research has given the stock a "strong sell" rating.
• Kenvue recently declared a dividend increase to $0.2075 per share, yielding about 4.1%, which is higher than the previous dividend of $0.21.

Curi RMB Capital LLC lowered its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 15.2% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 474,957 shares of the company's stock after selling 85,212 shares during the period. Curi RMB Capital LLC's holdings in Kenvue were worth $11,389,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Pittenger & Anderson Inc. purchased a new stake in shares of Kenvue during the first quarter valued at approximately $30,000. TruNorth Capital Management LLC purchased a new position in Kenvue in the 1st quarter worth approximately $36,000. Truvestments Capital LLC bought a new position in Kenvue in the 1st quarter valued at approximately $37,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after purchasing an additional 1,287 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of Kenvue by 120.6% in the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock worth $41,000 after purchasing an additional 929 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Royal Bank Of Canada dropped their price objective on Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a research report on Friday, August 8th. Barclays dropped their price target on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Tuesday, July 15th. Bank of America decreased their price objective on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a report on Tuesday, July 15th. UBS Group dropped their target price on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a report on Thursday, July 17th. Finally, Citigroup cut their price objective on Kenvue from $24.50 to $22.00 and set a "neutral" rating for the company in a report on Tuesday, July 15th. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $24.21.

Kenvue Stock Performance

Shares of NYSE KVUE traded down $0.18 during trading on Monday, hitting $18.44. The company had a trading volume of 56,120,054 shares, compared to its average volume of 18,165,861. Kenvue Inc. has a 12 month low of $17.15 and a 12 month high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The firm has a market capitalization of $35.39 billion, a P/E ratio of 24.92, a price-to-earnings-growth ratio of 2.67 and a beta of 0.83. The stock has a 50 day simple moving average of $21.37 and a 200 day simple moving average of $22.38.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same period in the prior year, the firm posted $0.32 EPS. The firm's quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.5%. The ex-dividend date was Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. Kenvue's payout ratio is 112.16%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.